HIBio

Foshan, China Founded: 2021 • Age: 5 yrs Acquired By Biogen
Precision medicines for autoimmune and inflammatory diseases are developed.
Request Access

About HIBio

HIBio is a company based in Foshan (China) founded in 2021 by Travis Murdoch was acquired by Biogen in May 2024.. HIBio has raised $215 million across 2 funding rounds from investors including Biogen, Arch Venture Partners and Arkin. HIBio offers products and services including Neurological Therapies. HIBio operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.

  • Headquarter Foshan, China
  • Founders Travis Murdoch
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $215 M (USD)

    in 2 rounds

  • Latest Funding Round
    $95 M (USD), Series B

    Jan 04, 2024

  • Investors
    Biogen

    & 6 more

  • Employee Count
    Employee Count
  • Acquired by
    Biogen

    (May 22, 2024)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of HIBio

HIBio offers a comprehensive portfolio of products and services, including Neurological Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Treatments for neurological disorders like Alzheimer's

People of HIBio
Headcount 10-50
Employee Profiles 6
Employee Profiles
People
Teresita Arenzana Delfino
Associate Director | Translational Sciences
People
Hannah Lock
Senior Associate Scientist, Immunology
People
Guorui Xie
Senior Scientist | Biomarker/translational Immunology | Hi-bio
People
Jonathan Carroll
Senior Research Software Engineer

Unlock access to complete

Funding Insights of HIBio

HIBio has successfully raised a total of $215M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $95 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $95.0M
  • First Round

    (01 Nov 2022)

  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2024 Amount Series B - HIBio Valuation Alpha Wave Global
Nov, 2022 Amount Series B - HIBio Valuation Arch Venture Partners , Monograph
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in HIBio

HIBio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, Arch Venture Partners and Arkin. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm focused on growth-stage companies
Founded Year Domain Location
Private investment firm focused on multiple sectors
Founded Year Domain Location
Jeito Capital is focused on financing medical innovation globally.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by HIBio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - HIBio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Hibio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of HIBio

HIBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Therapies for immunological and neurological disorders are developed.
domain founded_year HQ Location
Plasma-derived therapies are developed to treat multiple diseases.
domain founded_year HQ Location
Small molecule protein degraders are developed for various disorders.
domain founded_year HQ Location
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
domain founded_year HQ Location
Developer of novel protein-based therapeutics using machine learning and biological engineering
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about HIBio

When was HIBio founded?

HIBio was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is HIBio located?

HIBio is headquartered in Foshan, China. It is registered at Foshan, Guangdong, China.

Who is the current CEO of HIBio?

Travis Murdoch is the current CEO of HIBio. They have also founded this company.

Is HIBio a funded company?

HIBio is a funded company, having raised a total of $215M across 2 funding rounds to date. The company's 1st funding round was a Series B of $120M, raised on Nov 01, 2022.

What does HIBio do?

HIBio was founded in 2021 in Foshan, China, by Travis Murdoch, who serves as CEO. Operations focus on the biotechnology sector, where precision medicines targeting autoimmune and inflammatory diseases are developed. Research and development activities are centered in China, with an emphasis on therapeutic innovations for unmet medical needs in immunology. The companys domain, hibio.com, supports its ongoing efforts in this field.

Who are the top competitors of HIBio?

HIBio's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.

What products or services does HIBio offer?

HIBio offers Neurological Therapies.

Who are HIBio's investors?

HIBio has 7 investors. Key investors include Biogen, Arch Venture Partners, Arkin, Alpha Wave Global, and Viking Global Investors.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available